Colivelin
Colivelin is a hybrid neuroprotective peptide combining activity-dependent neurotrophic factor (ADNF) fragment with humanin, demonstrating potent protection against Alzheimer's-related neurotoxicity through dual STAT3 and humanin receptor signaling.
Colivelin is a synthetic chimeric peptide created by fusing the activity-dependent neurotrophic factor-9 (ADNF-9, also called SAL) sequence with a humanin derivative. Designed to combine the neuroprotective mechanisms of both parent peptides, colivelin demonstrates significantly greater potency than either component alone in protecting neurons against Alzheimer's disease-related insults including amyloid-beta toxicity, presenilin mutations, and polyglutamine-induced cell death.
Overview
Colivelin was designed by Chiba and colleagues at Keio University to overcome limitations of individual neuroprotective peptides. The peptide consists of the ADNF-9 sequence (SALLRSIPA) linked to a stabilized humanin derivative (AGA-(C8R)HNG17). By combining two independent neuroprotective mechanisms into a single molecule, colivelin achieves synergistic protection against multiple neurodegenerative insults. The ADNF-9 moiety activates calcium/calmodulin-dependent protein kinase IV (CaMKIV) and downstream transcription factors, while the humanin component engages the CNTFR/WSX-1/gp130 trimeric receptor complex to activate JAK2/STAT3 signaling. This dual-mechanism design makes colivelin effective against a broader range of neurotoxic challenges than either parent peptide.
Mechanism of Action
Colivelin exerts neuroprotection through two distinct and complementary signaling pathways, each contributed by one of its component sequences.
ADNF-9 (SAL) pathway: The N-terminal ADNF-9 sequence activates intracellular calcium signaling through CaMKIV, which phosphorylates CREB (cAMP response element-binding protein) and drives transcription of pro-survival genes including BDNF, Bcl-2, and neurotrophic factors (Chiba et al., 2004). This pathway operates independently of the humanin receptor system and provides protection even when STAT3 signaling is pharmacologically blocked.
Humanin pathway: The C-terminal humanin derivative engages the heterotrimeric CNTFR/WSX-1/gp130 receptor complex, activating JAK2 and subsequently STAT3. Phosphorylated STAT3 dimerizes, translocates to the nucleus, and induces transcription of anti-apoptotic genes (Bcl-2, Bcl-xL, Mcl-1) while suppressing pro-apoptotic factors (Hashimoto et al., 2001). The C8R substitution in the humanin derivative prevents oxidative dimerization and enhances stability.
The convergence of both pathways on Bcl-2 family gene regulation, through independent upstream signals, creates redundancy that ensures neuroprotection even when one pathway is partially compromised -- a common scenario in aged or diseased neurons.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
In Vivo Cognitive Protection
Chiba et al. (2005) administered colivelin intracerebroventricularly to mice treated with amyloid-beta 25-35 and demonstrated complete prevention of spatial memory impairment in the Morris water maze test. Colivelin also prevented cholinergic neuron loss in the medial septum and preserved acetylcholine levels in the hippocampus, regions critical for memory formation and retrieval.
Polyglutamine Disease Protection
Expanded polyglutamine (polyQ) repeats cause neurodegeneration in Huntington's disease and spinocerebellar ataxias. Colivelin protects neurons from polyQ-induced cell death through both its STAT3-activating and CaMKIV-activating pathways, providing broader coverage than humanin alone, which shows reduced efficacy against certain polyQ constructs (Chiba et al., 2004).
Stroke and Ischemia Research
Subsequent research has explored colivelin's potential in ischemic brain injury. The dual-pathway activation provides both acute anti-apoptotic protection (humanin component) and longer-term neurotrophic support (ADNF-9 component), making it theoretically suited for the complex pathophysiology of stroke where both immediate cell death and delayed neurodegeneration occur.
Alzheimer's Disease Neuroprotection
Colivelin protects against all major Alzheimer's-related neurotoxic insults tested. Chiba et al. (2005) demonstrated that colivelin rescues neurons from cell death induced by familial Alzheimer's disease-linked presenilin-1 (V96M) and presenilin-2 (N141I) mutations, amyloid-beta 1-43 peptide, and the superoxide dismutase-1 mutant (A4V) associated with familial amyotrophic lateral sclerosis. Critically, colivelin maintained neuroprotective efficacy at concentrations 100- to 1000-fold lower than either ADNF-9 or humanin alone.
Safety Profile
Colivelin has demonstrated a favorable safety profile in preclinical studies. As a peptide composed of sequences derived from endogenous neuroprotective factors (ADNF and humanin), it operates within established physiological signaling cascades. No significant adverse effects have been reported in rodent studies at neuroprotective doses. The primary theoretical concern, shared with humanin, relates to sustained STAT3 activation potentially promoting survival of pre-malignant cells, though this has not been observed experimentally. The ADNF-9 component's calcium signaling effects are self-limiting due to negative feedback through phosphatases. Systemic exposure data and formal toxicology studies remain limited, and no human clinical trials have been conducted.
Pharmacokinetic Profile
- Half-life
- Not established in humans
Quick Start
- Route
- Subcutaneous injection, intracerebroventricular (ICV)
Molecular Structure
- Formula
- C119H206N32O35
- Weight
- 2645.1 Da
- CAS
- Not yet assigned
- PubChem CID
- 90477169
- Exact Mass
- 2644.5357 Da
- LogP
- -4.1
- TPSA
- 1040 Ų
- H-Bond Donors
- 36
- H-Bond Acceptors
- 38
- Rotatable Bonds
- 85
- Complexity
- 5960
Identifiers (SMILES, InChI)
InChI=1S/C119H206N32O35/c1-24-63(17)91(113(181)142-80(50-90(160)161)106(174)143-81(49-62(15)16)115(183)151-42-30-35-86(151)117(185)186)146-100(168)73(36-37-89(158)159)133-88(157)52-128-112(180)93(69(23)155)148-107(175)79(48-61(13)14)141-105(173)78(47-60(11)12)140-104(172)77(46-59(9)10)139-103(171)76(45-58(7)8)137-98(166)71(31-26-38-125-118(121)122)135-108(176)82(54-153)144-95(163)66(20)129-87(156)51-127-94(162)65(19)131-110(178)84-33-28-40-149(84)114(182)68(22)132-111(179)85-34-29-41-150(85)116(184)92(64(18)25-2)147-109(177)83(55-154)145-99(167)72(32-27-39-126-119(123)124)134-101(169)75(44-57(5)6)138-102(170)74(43-56(3)4)136-96(164)67(21)130-97(165)70(120)53-152/h56-86,91-93,152-155H,24-55,120H2,1-23H3,(H,127,162)(H,128,180)(H,129,156)(H,130,165)(H,131,178)(H,132,179)(H,133,157)(H,134,169)(H,135,176)(H,136,164)(H,137,166)(H,138,170)(H,139,171)(H,140,172)(H,141,173)(H,142,181)(H,143,174)(H,144,163)(H,145,167)(H,146,168)(H,147,177)(H,148,175)(H,158,159)(H,160,161)(H,185,186)(H4,121,122,125)(H4,123,124,126)/t63-,64-,65-,66-,67-,68-,69+,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,91-,92-,93-/m0/s1
PTTAQOYOJJTWFD-IBAOLXMASA-NResearch Protocols
intracerebroventricular Injection
Clinical Research Protocols Intracerebroventricular Administration (Rodent) [Chiba et al. After intracerebroventricular infusion, the peptide distributes throughout the cerebrospinal fluid with direct access to hippocampal and cortical tissue.
intraperitoneal Injection
Based on humanin pharmacokinetics, subcutaneous or intraperitoneal delivery is feasible, though blood-brain barrier penetration efficiency for the intact chimeric peptide requires further characterization.
subcutaneous Injection
Based on humanin pharmacokinetics, subcutaneous or intraperitoneal delivery is feasible, though blood-brain barrier penetration efficiency for the intact chimeric peptide requires further characterization. Systemic absorption following subcutaneous injection is expected to follow humanin-like kineti
Interactions
Peptide Interactions
Given colivelin's preservation of cholinergic neurons in the medial septum, combination with cholinesterase inhibitors (donepezil, rivastigmine) could provide complementary benefits: colivelin protecting cholinergic neurons from degeneration while cholinesterase inhibitors enhance signaling from ...
SS-31 protects mitochondrial function by stabilizing cardiolipin, while colivelin prevents the downstream apoptotic consequences of mitochondrial stress. As mitochondrial dysfunction is an early event in Alzheimer's pathogenesis, this combination targets complementary aspects of neurodegeneration.
Colivelin + Semax/Selank Semax (a synthetic ACTH fragment) and selank (a tuftsin analogue) provide neurotrophic and anxiolytic effects through distinct mechanisms.
Colivelin + Semax/Selank Semax (a synthetic ACTH fragment) and selank (a tuftsin analogue) provide neurotrophic and anxiolytic effects through distinct mechanisms.
Quality Indicators
What to look for
- Human clinical trials conducted
- Well-established safety profile
- Multiple peer-reviewed studies available
Caution
- Limited human data available
Frequently Asked Questions
References (9)
- [3]
- [8]
- [10]Kim et al -- Humanin and its analogs as therapeutic targets for age-related diseases Ageing Res Rev (2023)
- [2]
- [1]Chiba et al *J Neurosci Res* J Neurosci Res (2004)
- [4]Matsuoka *Recent Pat CNS Drug Discov* Recent Pat CNS Drug Discov (2009)
- [5]
- [6]
- [9]Matsuoka et al -- Colivelin ameliorates amyloid-beta-induced memory impairments through multiple neuroprotective pathways Pharmacol Biochem Behav (2015)
CNTF
Ciliary Neurotrophic Factor (CNTF) is a member of the IL-6 cytokine family that signals through the CNTFRα/LIFRβ/gp130 tripartite receptor complex to activate JAK/STAT3 signaling, with research applications in ALS, retinal degeneration, and obesity.
Cortagen
Cortagen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Pro) studied for its effects on central nervous system gene expression, chromatin remodeling, and neuroprotective signaling in neural tissues.